← Back to Search

Stem Cell Therapy

Knee OA Treated with Regenexx SD for Osteoarthritis

N/A
Waitlist Available
Led By Christopher Centeno, MD
Research Sponsored by Regenexx, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights
No Placebo-Only Group

Summary

The primary objective of this study is to determine the levels of proteins and/or cellular components of the synovial fluid that are indicative of microenvironment phenotypes of the osteoarthritic knee compared to unilateral unaffected joints pre-injection to 6 weeks post-Regenexx® SD treatment.

Eligible Conditions
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Median change in protein concentration or percentage of cellular subpopulations
Secondary study objectives
Incidence and time to re-injection/re-operation
Incidence and time to resolution of post-operative complications and adverse events
Mean Change in IKDC Scores from baseline to 6 weeks
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Knee OA Treated with Regenexx SDExperimental Treatment1 Intervention
20 subjects with unilateral knee osteoarthritis. Collection of synovial fluid from both knees will serve as the experimental condition, i.e. the osteoarthritic knee, and the matched control, i.e. the knee not demonstrating signs of osteoarthritis. Alterations in the concentration of the synovial fluid proteins and cellular components will be evaluated up to 6 weeks post-Regenexx® SD - Same Day Bone Marrow Concentrate Injection treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Regenexx SD
2013
N/A
~150

Find a Location

Who is running the clinical trial?

Regenexx, LLCLead Sponsor
14 Previous Clinical Trials
50,825 Total Patients Enrolled
4 Trials studying Osteoarthritis
185 Patients Enrolled for Osteoarthritis
Christopher Centeno, MDPrincipal InvestigatorCenteno-Schultz Clinic
12 Previous Clinical Trials
50,377 Total Patients Enrolled
3 Trials studying Osteoarthritis
137 Patients Enrolled for Osteoarthritis
~2 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top